SMMT Summit Therapeutics PLC

$20.49

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/2/2025

About Summit Therapeutics PLC

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.

Website: https://www.summittxinc.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1599298
Address
136A EASTERN AVENUE, MILTON PARK, ABINGDON, GB
Valuation
Market Cap
$18.15B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
46.70
Performance
EPS
$-0.31
Dividend Yield
—
Profit Margin
0.00%
ROE
-94.90%
Technicals
50D MA
$20.12
200D MA
$18.00
52W High
$33.89
52W Low
$2.10
Fundamentals
Shares Outstanding
738M
Target Price
$35.41
Beta
-0.46

SMMT EPS Estimates vs Actual

● Estimated
● Actual

SMMT News & Sentiment

Sep 24, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT - Summit Therapeutics ( NASDAQ:SMMT )
NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ( "Summit" or the "Company" ) SMMT. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sep 23, 2025 • Benzinga SOMEWHAT-BULLISH
Nvidia Meets Palantir, Rocket Lab On The '10-Bagger' Legends List - NVIDIA ( NASDAQ:NVDA )
Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom, showcasing the power and volatility of high-growth companies in a rapidly recovering market environment. NVDA stock is up 36% this year. See the real-time chart here
Sep 22, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
Sep 17, 2025 • Benzinga SOMEWHAT-BULLISH
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Biohaven ( NYSE:BHVN ) , Avient ( NYSE:AVNT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Sep 15, 2025 • Benzinga NEUTRAL
Opendoor? No Meme Stocks, Ring The Register: Jim Cramer - Lumentum Holdings ( NASDAQ:LITE ) , Hubbell ( NYSE:HUBB )
"We're going to have to move on," Cramer on Summit Therapeutics. See the trading strategy with a perfect track record in 2025 [currently 34-0] → On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ringing the register on Opendoor Technologies Inc. OPEN. "We don't want to be in a meme ...
Sep 11, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
Sentiment Snapshot

Average Sentiment Score:

0.091
50 articles with scored sentiment

Overall Sentiment:

Neutral

SMMT Reported Earnings

Apr 29, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Dec 31, 2024
Dec 31, 2024 (Pre market)
-0.0 Surprise
  • Reported EPS: $-0.06
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: -3.3%
Oct 30, 2024
Sep 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.08
  • Estimate: $-0.07
  • Whisper: —
  • Surprise %: -14.3%
Aug 06, 2024
Jun 30, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.09
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: -50.0%
May 01, 2024
Mar 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.06
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: 0.0%
Feb 20, 2024
Dec 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.05
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Nov 07, 2023
Sep 30, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.03
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Aug 09, 2023
Jun 30, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.02
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
May 11, 2023
Mar 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-1.43
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%

Financials